Comment on: an orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent
- PDF / 105,554 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 51 Downloads / 136 Views
REVIEW
Comment on: an orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent Xinxiao Li 1 & Renba Liang 1,2 Received: 13 September 2020 / Accepted: 26 October 2020 # Springer Science+Business Media, LLC, part of Springer Nature 2020
Summary Recently we read a paper in Investigational New Drugs “An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent”. Chalcone hybrid 9, a novel chalcone derivative, may be a promising agent for the treatment of hepatocellular carcinoma. However, there are some problems in this paper that are worthy of comment. Human hepatocellular carcinoma HepG2 cells from Shanghai Research Science Limited Company could generate xenograft in nude mice and chalcone hybrid 9 suppressed the growth of HepG2 tumor. However, according to the description of cell bank of Chinese Academy of Science and ATCC, HepG2 cells are no tumorigenic. Similarly, our lab also confirmed that HepG2 cells cannot demonstrate tumorigenic ability in nude mice. Therefore, this discrepancy raised our concern about HepG2 xenograft in the paper. Keywords Chalcone hybrid . HepG2 . Nude mice
Dear Editor, With great interest we read a paper in Investigational New Drugs “An orally antitumor chalcone hybrid inhibited HepG2 cells growth and migration as the tubulin binding agent” by Wang et al. [1]. We would like to congratulate Wang et al. for evaluating the anticancer activity of chalcone hybrid 9, a novel chalcone derivative, on hepatocellular carcinoma. Chalcone hybrid 9 inhibited HepG2 cells growth and migration and it may be a promising agent for the treatment of hepatocellular carcinoma. However, there are some problems in this paper that are worthy of comment and attention. In Wang’s report, human hepatocellular carcinoma HepG2 cells from Shanghai Research Science Limited Company could generate xenograft in nude mice and chalcone hybrid 9 suppressed the growth of HepG2 tumor (Fig. 7). However, according to the description of cell bank of Chinese Academy of Science (http://www.cellbank.org.cn/search-detail.php?id=
524) and ATCC (https://www.atcc.org/products/all/HB-8065. aspx#characteristics), HepG2 cells are no tumorigenic in nude mice. Similarly, our lab also confirmed that HepG2 cells cannot demonstrate tumorigenic ability in nude mice. Therefore, this discrepancy raised our concern about HepG2 xenograft in the paper.
Compliance with ethical standards This article does not contain any studies with human participants or animals performed by any of the authors. Conflict of interest Author Xinxiao Li declares that she has no conflict of interest. Author Renba Liang declares that he has no conflict of interest.
References 1.
* Renba Liang [email protected] 1
Department of Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China
2
Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, No. 71 He Di Road, Nanning 530021, Guangxi, China
Wang Y, Chen XY, Li Y, Wang Y, X
Data Loading...
